Last reviewed · How we verify
Verapamil + paroxetine
This combination uses verapamil (a calcium channel blocker) to inhibit drug efflux transporters, thereby increasing paroxetine (an SSRI) bioavailability and CNS penetration.
This combination uses verapamil (a calcium channel blocker) to inhibit drug efflux transporters, thereby increasing paroxetine (an SSRI) bioavailability and CNS penetration. Used for Depression (investigational combination to enhance SSRI efficacy).
At a glance
| Generic name | Verapamil + paroxetine |
|---|---|
| Sponsor | University of California, Irvine |
| Drug class | SSRI + calcium channel blocker combination |
| Target | P-glycoprotein (MDR1/ABCB1), L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Verapamil blocks P-glycoprotein and other efflux transporters that normally pump paroxetine out of cells and across the blood-brain barrier. By inhibiting these transporters, verapamil increases paroxetine concentrations in the brain and systemic circulation, potentially enhancing antidepressant efficacy at lower doses. This is a pharmacokinetic interaction strategy rather than a direct therapeutic mechanism.
Approved indications
- Depression (investigational combination to enhance SSRI efficacy)
Common side effects
- Hypotension
- Bradycardia
- Constipation
- Nausea
- Dizziness
Key clinical trials
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Management of Acute Tinnitus With Migraine Medications (PHASE4)
- Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities (PHASE4)
- Treatment of Tinnitus With Migraine Medications (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |